Platinum Investment Management Ltd. Has $2.03 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Platinum Investment Management Ltd. raised its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 30.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 74,900 shares of the company’s stock after buying an additional 17,670 shares during the quarter. Platinum Investment Management Ltd. owned 0.13% of Structure Therapeutics worth $2,031,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd increased its stake in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after buying an additional 553 shares during the period. GAMMA Investing LLC increased its stake in Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after buying an additional 1,122 shares during the period. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics in the 4th quarter valued at approximately $40,000. Assetmark Inc. increased its stake in Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock valued at $58,000 after buying an additional 719 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in shares of Structure Therapeutics by 29.8% during the 4th quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock worth $115,000 after purchasing an additional 971 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $21.11 on Wednesday. Structure Therapeutics Inc. has a fifty-two week low of $19.39 and a fifty-two week high of $62.74. The firm has a fifty day moving average price of $25.08 and a two-hundred day moving average price of $32.09. The company has a market cap of $1.21 billion, a PE ratio of -28.53 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on GPCR shares. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. Finally, JMP Securities restated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.